C-286An act to amend the Controlled Drugs and Substances Act and the Food and Drugs Act
An act to amend the Controlled Drugs and Substances Act and the Food and Drugs Act
Private member's bill, introduced in the House of Commons on June 16, 2026
- Status
- At second reading in the House of Commons since June 16, 2026
What it does
Allows psilocin and psilocybin to be used for medical treatment and makes some priority review requests for new drugs automatically approved.
What it does
- Allows psilocin and psilocybin to be treated as narcotics for the Narcotic Control Regulations, so they can be used for medical treatment under those rules.
- Excludes psilocin and psilocybin from the definition of “restricted drug” for Part J of the Food and Drug Regulations.
- Adds the same restricted drug definition to the Food and Drugs Act, again leaving out psilocin and psilocybin.
- Deems a request for priority review of a new drug submission to be granted when it is for psilocin, psilocybin, or a substance with a similar chemical structure.
Who it affects
- People seeking psilocin or psilocybin treatment
- Health care practitioners
- Drug makers
- People filing new drug submissions
- Health Canada
Topics
Background
The bill says its purpose is to improve access to hallucinogenic drug medical treatment and not to bypass existing approval processes for new drugs.
Where it is
House of Commons
First reading
Completed.
Second reading
Current stage. Now here
Committee
Not reached.
Report stage
Not reached.
Third reading
Not reached.
Senate
First reading
Not reached.
Second reading
Not reached.
Committee
Not reached.
Third reading
Not reached.
Royal assent
Royal assent
Not reached.
Introduced by an MP who is not a minister. These bills compete in a lottery for debate time, and most do not become law. How a bill becomes law
How the House voted
No recorded votes yet
Read the source
LEGISinfo status: Outside the Order of Precedence. Bill data from LEGISinfo, votes from openparliament.ca and the House of Commons. Last updated October 13, 2026.